Literature DB >> 6088747

Pharmacokinetics of ceftriaxone in neonates and infants with meningitis.

E Martin, J R Koup, U Paravicini, K Stoeckel.   

Abstract

The pharmacokinetics of ceftriaxone was studied in the plasma, urine, and cerebrospinal fluid of seven neonates and seven infants with meningitis. In addition, plasma and urine data were obtained in five neonates and one infant receiving ceftriaxone for other serious infections. All neonates younger than 14 days received daily doses of 50 mg/kg ceftriaxone; all other patients but two received 100 mg/kg. The average weight-corrected values for total body clearance (ClT), volume of distribution (Vdss), and biologic half-life (t 1/2) were 0.37 ml/min/kg, 0.45 L/kg, and 16.2 hours in neonates younger than 1 week; 0.77 ml/min/kg, 0.48 L/kg, and 9.2 hours in neonates older than 1 week; and 1.03 ml/min/kg, 0.39 L/kg, and 7.1 hours in older infants, respectively. There was a significant difference in ClT and t 1/2 between the neonates younger and both neonates older than 1 week, and infants. The Vdss was not significantly different among the three age groups. The average renal clearance in neonates younger than 1 week (0.28 ml/min/kg was 70%, in neonates older than 1 week (0.54 ml/min/kg) was 77%, and in older infants (0.49 ml/min/kg) was 47% of ClT, indicating that nonrenal elimination was less developed in neonates. The quantitation of CSF diffusion of ceftriaxone was assessed by comparison of the areas under the CSF and plasma concentration-time curve. The mean ceftriaxone penetration into the CSF in neonates and infants with bacterial meningitis was 17%. On the other hand, penetration in patients with aseptic meningitis amounted to only 4%. Mean ceftriaxone concentrations in the CSF in patients with bacterial meningitis were 2.8 mg/L after 24 hours, exceeding by many times the minimum inhibitory concentration of the common meningitis pathogens at this time.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088747     DOI: 10.1016/s0022-3476(84)80032-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  24 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; J Bauchet; F Faurisson; P Gehanno; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Authors:  Marija Djukic; Martin Munz; Fritz Sörgel; Ulrike Holzgrabe; Helmut Eiffert; Roland Nau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

Review 4.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  beta-lactam antibiotics in the treatment of neuroborreliosis in children: preliminary results.

Authors:  M M Millner; G H Thalhammer; P Dittrich; K D Spork; M Brunner; A Georgopoulos
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

6.  Ceftriaxone versus penicillin G in the short-term treatment of meningococcal meningitis in adults.

Authors:  K Marhoum el Filali; M Noun; A Chakib; M Zahraoui; H Himmich
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

Review 7.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

8.  Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis.

Authors:  J L Gaillard; C Silly; A Le Masne; B Mahut; F Lacaille; G Cheron; V Abadie; P Hubert; V Matha; C Coustere
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

9.  Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.

Authors:  E Martin; S Fanconi; P Kälin; C Zwingelstein; C Crevoisier; W Ruch; R Brodersen
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

10.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.